P21-Activated Kinase 1 (PAK1) as a Therapeutic Target in BRAF Wild-Type Melanoma
Christy C. Ong(Gene Therapy Laboratory), Klaus P. Hoeflich(Pivot), Diana Jakubiak(MRC Weatherall Institute of Molecular Medicine), Jarrod R. Tremayne, Marcia Belvin(CytomX Therapeutics (United States)), Joachim Rudolph, Hartmut Koeppen, Mark R. Middleton(University of Oxford), Peter M. Haverty, Adrian L. Harris(University of Oxford), Lori S. Friedman, Wei Zhou(Broad Institute), Elizabeth M. Blackwood, Yibing Yan(Anhui Medical University), Marcin Kowanetz, Richard J. Lisle(MRC Weatherall Institute of Molecular Medicine), Adrian M. Jubb(Allogene Therapeutics (United States))
Cited by 88
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k